AUTL Share Price Performance
Recent AUTL News & Updates
No updates
Autolus Therapeutics plc Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 12, 2025
- Earnings per share (EPS)
- -0.89
- Gross Margin
- -1,620.50%
- Net Profit Margin
- -2,642.69%
- Debt/Equity Ratio
- 68.3%
Autolus Therapeutics plc Competitors
About AUTL
- Founded
- 2014
- Employees
- 649
- CEO
- WebsiteView website
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
U.K. Market Performance
- 7 Days: -2.5%
- 3 Months: 17.0%
- 1 Year: 12.4%
- Year to Date: 12.2%
Over the last 7 days, the market has dropped 2.5%, driven by a pullback of 2.3% in the Financials sector. In the last year, the market is actually up 12%. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading